Hesperos, Inc. works along side industry partners to provide key insight into their drug compounds, which in the past were only possible in clinical trials. Our scientists collaborate with those working on compounds so that each party understands abilities and limitations of the technology. Each study is unique and tailored to the goals of our clients, to give our clients the insights which they value most.
Bringing a drug to market is estimated to take over a decade of research and cost $2.6 Billion. The vast majority of the time and money is wasted on drugs that will ultimately fail. Hesperos, Inc. creates physiologically based pharmacokinetic models of compounds which can accurately predict the which will ultimately fail in the transition from animal models to clinical trials. These insights can now be predicted before valuable time and resources are invested. Read the full publication.
Aside from the ethical considerations of using live animal subjects to test drugs, animal testing is woefully inaccurate. For every 50 drugs that are determined to be safe for animals, only one proves safe in humans, and the FDA approval process for drugs based on animal testing is a long one as a result. By providing a platform for testing in the context of human metabolism, as opposed to animal models, our systems have the potential to eliminate the use of animals in preclinical trials. We have been recognized for our efforts with the international 2015 Lush Prize for Science.
As researchers aim to tackle more complex diseases, their need for high quality data is increasing. Our systems provide access to quickly test new compounds on both healthy and disease state models. The ability to generate large data sets allows Hesperos as well as outside researchers to discover trends leading to the identification of mechanisms of both disease and therapy.